GSK plc American Depositary Shares (Each representing two Ordinary Shares)
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK): 6 pipeline candidates · ~1 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.0 months
D/E 2.83 · 0% dilution
Lead: Phase 3
6 candidates
N/A
N/A
A transparent, data-derived signal for GSK plc American Depositary Shares (Each representing two Ordinary Shares)across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$104.2B
Cash
$761.0M
Quarterly Burn
$16.6B
Runway
1.0 mo
Revenue
$32.7B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| belimumab 10mg/kg | Phase 2 |
| blu-5937 | Phase 3 |
| blu-5937 er | Phase 3 |
| blu-5937 ir | Phase 3 |
| camlipixant | Phase 1 |
| idrx-42 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,031
Total value held
$17.31B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 67,661,646 | $3.73B |
| dodge & cox | 58,662,974 | $3.24B |
| primecap management co/ca/ | 25,204,538 | $1.39B |
| wellington management group llp | 11,717,613 | $646.7M |
| morgan stanley | 11,030,651 | $608.8M |
| goldman sachs group inc | 10,289,114 | $567.9M |
| royal bank of canada | 7,506,786 | $414.3M |
| state street corp | 5,998,486 | $334.0M |
| holocene advisors, lp | 5,518,433 | $304.6M |
| mondrian investment partners ltd | 4,987,393 | $275.3M |
Showing top 10 of 1,031 institutional holders of GSK plc American Depositary Shares (Each representing two Ordinary Shares). Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in GSK plc American Depositary Shares (Each representing two Ordinary Shares)'s pipeline?
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GSK plc American Depositary Shares (Each representing two Ordinary Shares)'s lead drug candidate?
GSK plc American Depositary Shares (Each representing two Ordinary Shares)'s most advanced tracked candidate is belimumab 10mg/kg (Phase 2) for Systemic Lupus Erythematosus.
What is GSK plc American Depositary Shares (Each representing two Ordinary Shares)'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GSK plc American Depositary Shares (Each representing two Ordinary Shares) has approximately 1.0 months of cash runway.
What is GSK plc American Depositary Shares (Each representing two Ordinary Shares)'s market capitalization?
GSK plc American Depositary Shares (Each representing two Ordinary Shares)'s market capitalization is approximately $104.2B.
Who is the CEO of GSK plc American Depositary Shares (Each representing two Ordinary Shares)?
Mr. Luke Victor Miels is the chief executive officer of GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK).
Get the full picture on GSK plc American Depositary Shares (Each representing two Ordinary Shares)
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.